Investing Profile

Adam Koppel

InvestorVC
Managing Director at Bain Capital Life Sciences
baincapital.comMassachusetts
Photo of Adam Koppel, Managing Director at Bain Capital Life Sciences

Signal uses Gmail to reveal intro paths. Email content is never read.

Sign in with Google →
cb
Bain Capital Life Sciences Managing Director
$100K - $5.0M
$1.5M
10
CompanyStageDateRound SizeTotal Raised
Areteia Therapeutics
Series AFeb 2024$75M
Series AJul 2022$350M
$430M
Co-investors: Paul Berns (ARCH Venture Partners)
Solid Biosciences
Post Ipo EquityJan 2024$110M
Post Ipo EquitySep 2022$75M
$180M
Co-investors: Luis Valdich (Citi Ventures)
Synapticure
SeedFeb 2022$6M
$16M
Co-investors: Ron Conway (SV Angel), Ronald Conway Sr. (SV Angel), Joe Kraus (GV (Google Ventures)), Jeff Huber (Triatomic Capital), David Hodgson (General Atlantic), Ben Silbermann
ViaCyte
Series DNov 2018$80M
$140M
Co-investors: Asish Xavier (Johnson & Johnson Innovation), Heath Lukatch (Red Tree Venture Capital)
Cerevel Therapeutics
Private EquityOct 2018$350M
$350M
Co-investors: Chris Gordon (Bain Capital)
Aptinyx
Series BDec 2017$70M
$140M
Co-investors: Liam Ratcliffe (Access Biotechnology)
InflaRx
Series DOct 2017$55M
$55M
PTC Therapeutics
Private EquityMar 2013$60M
$130M
Co-investors: Andrew Schwab (5am Ventures), Rich Aldrich (Longwood Fund)